Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Business & Finance News, In Brief

Executive Summary

Generic Lovenox, Alcon Acquisition Driving Novartis Growth

You may also be interested in...



Amphastar Lawsuit Over Heparin Shipments Suggests Lovenox ANDA Approval May Be Far Off

Allegations in Amphastar Pharmaceuticals’ lawsuit over FDA detention of heparin raw ingredient shipments suggest approval of its enoxaparin ANDA, the generic of Sanofi-Aventis’ low-molecular weight heparin Lovenox, is far from imminent.

Amphastar Lawsuit Over Heparin Shipments Suggests Lovenox ANDA Approval May Be Far Off

Allegations in Amphastar Pharmaceuticals’ lawsuit over FDA detention of heparin raw ingredient shipments suggest approval of its enoxaparin ANDA, the generic of Sanofi-Aventis’ low-molecular weight heparin Lovenox, is far from imminent.

Roche Gets Reprieve On Avastin For Breast Cancer With Delay At FDA

FDA extends user fee date in lieu of reaching decision on whether or not to pull the breast cancer approval for bevacizumab.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052744

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel